Gapping up
In reaction to strong earnings/guidance:
- RBBN +18.9%, HABT +10.1%, EXAS +10%, BEAT +9.9%, SSW +9.3%, IGT +8.4%, ACAD +8.1%, EBAY +6.9%, YUMC +6.7%, FEYE +6.5%, DENN +6.4%, WLL +5.6%, EL +5.2%, FB +5.1%, TX +4.7%, QNST +4.5%, EVTC +4.2%, YUM +4.1%, TMUS +4%, UTHR +3.9%, CXO +3.8%, SNY +3.8%, CAI +3.5%, BG +3.2%, ICPT +3.2%, BJRI +3.1%, CRTO +3%, BAND +2.9%, HFC +2.8%, AINV +2.6%, SAN +2.5%, TENB +2.2%, CAKE +1.9%, STNG +1.8%, MGM +1.6%, ZEN +1.6%, TEF +1.6%, CHT +1.6%, EPD +1.5%, ADP +1.3%, ETR +1.3%, GNW +1.2%, OKE +1%, CDW +0.9%, .
M&A news:
- LKSD +23.7% (to be acquired by Quad/Graphics (QUAD) for approximately $1.4 bln in stock)
- ARNC +8.1% (on reports of Apollo Global (APO) M&A talks)
- NWL +1.8% (ticking higher on reports the company is nearing deal to sell Jostens)
Select FAANG related names showing strength:
- NFLX +2.3%, AMZN +1.9%, GOOGL +1.4%, AAPL +0.8%
Other news:
- KMPH +20.2% (KemPharm enters into license agreement with KVK Tech for the commercialization of APADAZ)
- KIN +15.4% (announces positive topline results for pilot effectiveness study of KIND-016)
- ACAD +8.1% (announces 'positive' top-line results from CLARITY study in major depressive disorder)
- CERC +7.1% (Cerecor receives Rare Pediatric Disease Designation from FDA for CERC-801)
- MMI +5.3% (to join S&P SmallCap 600)
- SAGE +2.6% (FDA publishes briefing documents ahead of November 2 AdCom on brexanolone)
- PZZA +1.6% (following late surge higher on reports of competing interest from several PE firms)
Analyst comments:
- ASML +1.8% (upgraded to Buy from Hold at Santander)
- CMI +1.2% (upgraded to Neutral at JP Morgan)
- CF +1.1% (upgraded to Buy at BofA/Merrill)
- GE +1% (upgraded to Buy at UBS)